Open AccessAzithromycin in Coronavirus Disease-19: What We Know?
Author(s) -
Ashok D. Agrawal
Publication year - 2020
Publication title -
open access macedonian journal of medical sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.288
H-Index - 17
ISSN - 1857-9655
DOI - 10.3889/oamjms.2020.4843
Subject(s) - medicine , azithromycin , hydroxychloroquine , bronchiectasis , cystic fibrosis , coronavirus , adverse effect , covid-19 , disease , chronic bronchitis , antibiotics , intensive care medicine , lung , infectious disease (medical specialty) , microbiology and biotechnology , biology
Azithromycin (AZM) is a broad-spectrum antibiotic with anti-inflammatory and immunomodulatory properties. It is particularly used in chronic lung diseases including chronic obstructive pulmonary disease, asthma, interstitial lung diseases, bronchiectasis, and cystic fibrosis. AZM has not approved for the treatment of viral infections, but some study supported its antiviral activity. Recently, few studies are emphasized used AZM in combination with chloroquine/hydroxychloroquine for the treatment of novel coronavirus disease-2019 (COVID-19). The present review highlighted uses, dosage, and adverse effects of AZM in COVID-19 based on available literature.